Last update 21 Nov 2024

Anselamimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Fibril-reactive monoclonal antibody 11-1F4
+ [2]
Target
Mechanism
APP inhibitors(Beta amyloid A4 protein inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (US), Orphan Drug (EU)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Immunoglobulin Light-Chain AmyloidosisPhase 3
RU
03 Nov 2020
Immunoglobulin Light-Chain AmyloidosisPhase 3
CA
03 Nov 2020
Immunoglobulin Light-Chain AmyloidosisPhase 3
AU
03 Nov 2020
Immunoglobulin Light-Chain AmyloidosisPhase 3
BR
03 Nov 2020
Immunoglobulin Light-Chain AmyloidosisPhase 3
DE
03 Nov 2020
Immunoglobulin Light-Chain AmyloidosisPhase 3
ES
03 Nov 2020
Immunoglobulin Light-Chain AmyloidosisPhase 3
IT
03 Nov 2020
Immunoglobulin Light-Chain AmyloidosisPhase 3
BR
03 Nov 2020
Immunoglobulin Light-Chain AmyloidosisPhase 3
GB
03 Nov 2020
Immunoglobulin Light-Chain AmyloidosisPhase 3
US
03 Nov 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
Immunoglobulin Light-Chain Amyloidosis
immunoglobulin light chain
22
CAEL-101 infusion
(smsgrqdcsw) = ejazvceuil kaaiokatss (jjeoealvqy )
Positive
04 Sep 2024
(Historical control group)
(smsgrqdcsw) = hovmuxebpi kaaiokatss (jjeoealvqy )
Phase 3
Immunoglobulin Light-Chain Amyloidosis
First line
N-terminal pro b-type natriuretic peptide (NT-proBNP) | involved/uninvolved free light chain difference (dFLC)
-
Anselamimab + CyBorD ± daratumumab
(zmtnpddllr) = jlyrqwrvvv rwevevfrsa (jzvvxqheeu, 2476 - 5758)
Positive
14 May 2024
Placebo + CyBorD ± daratumumab
(zmtnpddllr) = mrztwobirj rwevevfrsa (jzvvxqheeu, 10254 - 22884)
Phase 1
22
(jgziildnen) = No delayed adverse events occurred hycjzfcyob (pehjtmunem )
Positive
31 May 2023
Phase 2
13
CAEL-101+CyBorD
rietvkttnl(xuojggqxxa) = znswchhqjr zphvfqwmtk (ihttyoanqi )
-
09 Jun 2021
Phase 2
13
(oxgdwqvltv) = none siidjdlvij (qcrdcxmojn )
Positive
05 Nov 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free